Redefining Drug Delivery

We are working with partners to improve the lives of patients. Working with Vetter, we are commercializing microneedle delivery systems to meet the needs of both patients and biopharmaceutical companies.

 

No obligation technology evaluation.

Microdermics will work with you to design a proof-of-concept animal study to address your questions and validate our hollow microneedle drug delivery platform on a product-by-product basis.

Visit our TECHNOLOGY page to see examples of the product opportunities we are working on.

If you have questions about the capabilities of our microneedle platform, please contact us today to learn more.


Quotes from our supporters

Shoreline has been an active investor in the drug formulation and delivery space for some time. When first presented with the Microdermics story it immediately resonated with us. We are always on the lookout for innovative technologies that give the end user a more convenient and less invasive experience and provides superior efficacy for the drugs or vaccines being delivered. Their unique approach addressed both of these and we are delighted to be part of this exciting opportunity.
— Peter Craddock, Managing Director of Shoreline Ventures
Our investment in Microdermics is an example of finding an excellent, well-run company providing a solution to a global need. We are so excited to support development and commercialization for this delivery system, which will be beneficial and have a huge impact to so many around the world.
— Ray Chan, founding partner of K5 Ventures
Microdermics’ innovative solution, experienced team, and great potential for positive health impact make it a great addition to the high calibre of new ventures that continue to bloom here at UBC.
— Todd Farrell, President e@UBC Seed Fund